Literature DB >> 18718694

Synthesis and in vitro antimicrobial activity of some novel substituted benzimidazole derivatives having potent activity against MRSA.

Meral Tunçbilek1, Tuluğ Kiper, Nurten Altanlar.   

Abstract

The novel benzimidazole derivatives (3, 5, 8, 9, 12-14, 18-41) were prepared in this paper and the antimicrobial activities of these compounds against Staphylococcus aureus, methicillin-resistant S. aureus (MRSA, standard and clinical isolates), Bacillus subtilis, Escherichia coli and Candida albicans were evaluated. Compounds 24-26 which have no substitution of N-1 position displayed better antibacterial activities than those of standards (ciprofloxacin, ampicillin and sultamicillin) against both the drug-resistant bacteria (MRSA, standard and clinical isolates). These derivatives (24-26), 2,5,6-trihalogenobenzimidazole analogues (8, 12), 5,6-dichloro-2-amino derivative (13), and 5-chloro-2-(4-benzyloxyphenyl)benzimidazole (35) exhibited the most potent antibacterial activity with MIC 3.12 microg/ml against S. aureus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718694     DOI: 10.1016/j.ejmech.2008.06.026

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  13 in total

Review 1.  Therapeutic targets for the treatment of microsporidiosis in humans.

Authors:  Bing Han; Louis M Weiss
Journal:  Expert Opin Ther Targets       Date:  2018-11-01       Impact factor: 6.902

2.  Ethyl 1-(2-hy-droxy-eth-yl)-2-phenyl-1H-benzimidazole-5-carboxyl-ate.

Authors:  Nurasyikin Hamzah; Shafida Abd Hamid; Aisyah Saad Abdul Rahim; Mohd Mustaqim Rosli; Hoong-Kun Fun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-06-26

3.  High Throughput Screening Identifies a Novel Compound Protecting Cardiomyocytes from Doxorubicin-Induced Damage.

Authors:  Szabolcs Gergely; Csaba Hegedűs; Petra Lakatos; Katalin Kovács; Renáta Gáspár; Tamás Csont; László Virág
Journal:  Oxid Med Cell Longev       Date:  2015-06-07       Impact factor: 6.543

4.  Synthesis, Antimicrobial, and Computational Evaluation of Novel Isobutylchalcones as Antimicrobial Agents.

Authors:  Afzal Basha Shaik; Rajendra Prasad Yejella; Shahanaaz Shaik
Journal:  Int J Med Chem       Date:  2017-12-26

5.  Discovery of new imidazole derivatives containing the 2,4-dienone motif with broad-spectrum antifungal and antibacterial activity.

Authors:  Chunli Liu; Ce Shi; Fei Mao; Yong Xu; Jinyan Liu; Bing Wei; Jin Zhu; Mingjie Xiang; Jian Li
Journal:  Molecules       Date:  2014-09-29       Impact factor: 4.411

6.  Pharmacological and Toxicological Screening of Novel Benzimidazole-Morpholine Derivatives as Dual-Acting Inhibitors.

Authors:  Nafiz Öncü Can; Ulviye Acar Çevik; Begüm Nurpelin Sağlık; Yusuf Özkay; Özlem Atlı; Merve Baysal; Ümide Demir Özkay; Özgür Devrim Can
Journal:  Molecules       Date:  2017-08-19       Impact factor: 4.411

7.  Design and Synthesis of Benzimidazole-Chalcone Derivatives as Potential Anticancer Agents.

Authors:  Cheng-Ying Hsieh; Pi-Wen Ko; Yu-Jui Chang; Mohit Kapoor; Yu-Chuan Liang; Hui-Hsien Lin; Jia-Cherng Horng; Ming-Hua Hsu
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

8.  The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant Staphylococcus aureus.

Authors:  Nagendran Tharmalingam; Rajamohammed Khader; Beth Burgwyn Fuchs; Eleftherios Mylonakis
Journal:  Front Microbiol       Date:  2019-07-17       Impact factor: 5.640

Review 9.  Antimicrobial potential of 1H-benzo[d]imidazole scaffold: a review.

Authors:  Sumit Tahlan; Sanjiv Kumar; Balasubramanian Narasimhan
Journal:  BMC Chem       Date:  2019-02-04

10.  Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.

Authors:  Fat-Moon Suk; Chao-Lien Liu; Ming-Hua Hsu; Yu-Ting Chuang; Jack P Wang; Yi-Jen Liao
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.